UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): October 2, 2020
iBio, Inc.
(Exact name of registrant as specified in charter)
Delaware
(State or other jurisdiction of incorporation)
| 001-35023 | 26-2797813 |
| (Commission File Number) | (IRS Employer Identification No.) |
8800 HSC Parkway
Bryan, TX 77807
(Address of principal executive offices and zip code)
(302) 355-0650
(Registrant’s telephone number including area code)
600 Madison Avenue, Suite 1601
New York, NY 10022-1737
(Former Name and Former Address)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.001 par value per share | IBIO | NYSE American |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01. Other Events.
On October 2, 2020, iBio, Inc., a Delaware corporation (the “Company”), issued a press release relating to its entry into a Master Services Agreement with Boston-based Safi Biosolutions, Inc. (“Safi Bio”) to evaluate the Company’s FastPharming® System for the expression of key proteins to be used in the bioprocessing of Safi Bio’s blood cell therapy products and the Company’s investment in Safi Bio in the form of a convertible note in the principal amount of $1,500,000.
The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit is filed with this Current Report on Form 8-K:
| Exhibit Number | Description | |
| 99.1 | Press Release issued by iBio, Inc. on October 2, 2020 | |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| IBIO, INC. | |||
| Date: October 2, 2020 | By: | /s/ Thomas F. Isett | |
| Name: Thomas F. Isett | |||
| Title: Chairman and Chief Executive Officer | |||